Lacerenza, S.Moura, D.Pena-Chilet, M.Hindi, N.Dopazo, J.Sanchez-Bustos, P.Grignani, G.Martinez-Trufero, J.Redondo, A.Valverde, C.Stacchiotti, S.Lopez-Pousa, A.D'Ambrosio, L.Perez-Vega, H.Collini, P.Lopez-Martin, J. A.Martin-Broto, J.2025-01-072025-01-072021-09-21Lacerenza, S., Moura, D., Pena-Chilet, M., Hindi, N., Dopazo, J., Sanchez-Bustos, P., et al. Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups. Ann. Oncol; 2021-09-21; (32); S11180923-7534https://hdl.handle.net/10668/27455Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.enHumansProgrammed Cell Death 1 ReceptorImmunotherapyAngiogenesisB7-H1 AntigenNivolumabSunitinibSarcomaImmunomodulationconference outputRestricted AccessSarcomaEficaciaHuesosSunitinibPacientesInmunoterapiaTejidosTerapéutica10.1016/j.annonc.2021.08.8661569-8041https://doi.org/10.1016/j.annonc.2021.08.866700527703083